Blastic plasmacytoid dendritic cell neoplasm (BPDCN)

Why it matters

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) may be rare, but its impact is significant. This hematologic malignancy, arising from precursor dendritic cells that often appear as skin lesions and low level of blood cells. Presents unique challenges in diagnosis, treatment, and prognosis. BPDCN can quickly evolve into aggressive leukemia, with a median survival of only 8-14 months post-diagnosis. Early detection is crucial, but the lack of standardised treatment guidelines and the under recognition of BPDCN cause delays in detection, what may lead to misdiagnosis, and ultimately causing poorer outcomes.

Understanding BPDCN is not only essential for healthcare providers but also for policymakers, cancer patients, caregivers, and survivors. By raising awareness of BPDCN, we aim to empower individuals with knowledge about this rare cancer, facilitating earlier and accurate diagnosis, access to appropriate treatments, and improved support networks.

CPE’s Action and Plans

CPE is dedicated to enhancing the well-being of cancer patients across Europe. Aligned with its mission and values, CPE is leading a series of initiatives to raise awareness of BPDCN. These efforts will encompass the distribution of educational materials, including the development and publication of a fact sheet, available on this page, across social media platforms. Furthermore, CPE is organizing publicly accessible educational webinars to disseminate knowledge about BPDCN.

In addition, an advisory committee comprised of members from the cancer patients’ community and healthcare providers has already been established. This committee plays a pivotal role in providing insights and guidance throughout the project, ensuring its effectiveness and relevance.

Through these concerted efforts, CPE endeavours to shed light on BPDCN, facilitate informed decision-making, and ultimately improve outcomes for individuals affected by this rare cancer.